Introduction
============

Spontaneous regression of a malignancy is defined as the partial or complete disappearance of malignant disease without any medical treatment.[@b1] This phenomenon is extremely rare, with an estimated incidence of less than one in 60 000--100 000 cases.[@b1]

Spontaneous regression has most often been noted in malignant melanoma (0.22--0.27%), renal cell cancer (0.3--4.0%), low-grade non-Hodgkins's lymphoma (3.7--15%), chronic lymphocytic leukemia (3.7--15%), and neuroblastoma in children (10%).[@b2],[@b3] The phenomenon is extremely rare in non-small cell lung cancer (NSCLC), and only two of the 176 tumors with spontaneous regression reported by Cole were lung cancer (1 squamous cell carcinoma and 1 undifferentiated).[@b1] We observed a rare and interesting case of lung large cell neuroendocrine carcinoma (LCNEC) that regressed spontaneously, then progressed rapidly.

Case report
===========

An 85-year-old woman with a history of smoking presented with an abnormal shadow on chest X-ray, which was performed as part of a pre-operative evaluation for osteoarthritis of the knee in December 2012. A chest computed tomography (CT) scan revealed a 2.8 cm nodule in the right upper lung lobe (Fig [1a](#fig01){ref-type="fig"}) and fluorodeoxyglucose--positron emission tomography (FDG-PET) showed uptake only within the nodule. Although transbronchial lung biopsy (TBLB) was negative, cytology of bronchoalveolar lavage fluid from the right upper bronchi showed atypical cells suspicious for malignancy.

![Chest computed tomography scans showing the tumor shadow in the right upper lung lobe (in chronological order). The tumor shadow size and doubling times are presented. The patient underwent three biopsies. In July 2013, she was diagnosed with rheumatoid arthritis and began to receive glucocorticoid treatment. TBLB: transbronchial lung biopsy, US: ultrasound.](tca0006-0655-f1){#fig01}

The patient was referred to our hospital for curative pulmonary resection in March 2013. Her physical examination was unremarkable, and her blood examination, including tumor markers, showed anemia with a hemoglobin value of 10.2 mg/dL. The cause of the anemia was not clear despite scrutiny. In April 2013, the size of the tumor shadow decreased from 2.8 to 1.8 cm (Fig [1b](#fig01){ref-type="fig"}). We strongly suspected the tumor was benign rather than malignant and planned to perform a follow-up imaging examination. The tumor shadow remained unchanged for the next three months (Fig [1c](#fig01){ref-type="fig"}). In July 2013, the patient was diagnosed with rheumatoid arthritis and began to receive glucocorticoid treatment. In January 2014, the tumor increased from 1.8 to 4.8 cm (Fig [1d](#fig01){ref-type="fig"}) and a TBLB of the tumor was performed with suspicions of inflammatory disease or malignancy; however results of the TBLB were inconclusive. A chest CT scan was repeated in June 2014 and showed that the tumor shadow had further enlarged to 8.6 cm, with swelling of the mediastinal lymph nodes and suspected invasion of the superior vena cava and chest wall (Fig [1e](#fig01){ref-type="fig"}). FDG-PET showed uptake within the tumor with a maximal standard uptake value of 23.6, but did not show uptake within the mediastinal lymph nodes. An ultrasound-guided biopsy of the tumor revealed a proliferation of tumor cells with large and irregular nuclei (Fig [2a](#fig02){ref-type="fig"}). We diagnosed primary lung cancer, cT4N0M0, stage IIIA, according to the TNM (tumor node metastasis) Classification of Malignant Tumors (7th edition).

![(a) Biopsy tissue. The tumor showed a proliferation of tumor cells with large and irregular nuclei and necrosis (hematoxylin and eosin \[H&E\] stain, × 200). (b--d) Surgical resected tissue. The histopathological findings from were similar to that from the biopsy tissue (b: H&E stain, × 40 and c: H&E stain, ×400, respectively). (d) We diagnosed a large cell neuroendocrine carcinoma based on immunohistochemical study; the tumor was positive for synaptophysin.](tca0006-0655-f2){#fig02}

A right upper lobectomy with lymph node dissection in the hilum and right upper mediastinum was performed. Although the tumor had invaded the mediastinal fat tissue and parietal pleura, it did not invade the superior vena cava. The patient experienced a good postoperative course with no complications. On pathologic examination, the tumor was 7.5 cm in diameter and invaded the mediastinal fat tissue, but the lymph nodes did not show any evidence of metastasis. The histopathological results were similar to those from the biopsied tissue, and we diagnosed lung LCNEC, pathological stage IIIA (T4N0M0), based on immunohistochemical studies. The tumor was positive for synaptophysin, thyroid transcription factor-1, and cytokeratin 7, and was negative for chromogranin, CD56, and p63 (Fig [2b](#fig02){ref-type="fig"}--[d](#fig02){ref-type="fig"}). The patient did not receive postoperative cytotoxic chemotherapy because of her own request and her advanced age.

Discussion
==========

Our patient presents the first reported case of lung LCNEC with spontaneous regression. Furthermore, there have been no reports of spontaneous regression followed by rapid progression in primary lung cancer. To the best of our knowledge, 25 NSCLC tumors with spontaneous regression have been previously reported, including reviews by Kappauf *et al*.[@b3] and Haruki *et al*[@b4] (Table [1](#tbl1){ref-type="table"}).[@b3]--[@b8],[@b10] Among these cases, 15 tumors were squamous cell carcinomas, eight were adenocarcinomas, three were large cell carcinomas, and one was NSCLC.

###### 

Previously reported cases of spontaneous regression in non-small cell lung cancer

  Case   Author                                                                             Year   Age/Gender   Histology
  ------ ---------------------------------------------------------------------------------- ------ ------------ -----------
   1     Blades *et al*.[†](#tf1-2){ref-type="table-fn"}                                    1954   59/M         SQ
   2     Boyd *et al*.[†](#tf1-2){ref-type="table-fn"}                                      1966   56/M         AD
   3     Margolis *et al*.[†](#tf1-2){ref-type="table-fn"}                                  1967   58/M         AD
   4     Emerson *et al*.[†](#tf1-2){ref-type="table-fn"}[‡](#tf1-3){ref-type="table-fn"}   1968   63/M         SQ
   5     Bell *et al*.[†](#tf1-2){ref-type="table-fn"}                                      1970   37/M         SQ
   6     Smith *et al*.[†](#tf1-2){ref-type="table-fn"}                                     1971   59/M         SQ
   7     Smith *et al*.[†](#tf1-2){ref-type="table-fn"}                                     1971   43/M         SQ
   8     Depierre *et al*.[†](#tf1-2){ref-type="table-fn"}                                  1984   57/M         SQ
   9     Kato *et al*.[‡](#tf1-3){ref-type="table-fn"}                                      1986   55/F         SQ
  10     Sperduto *et al*.[‡](#tf1-3){ref-type="table-fn"}                                  1988   61/M         SQ
  11     Papac *et al*.[†](#tf1-2){ref-type="table-fn"}                                     1990   62/F         AD
  12     Kappauf *et al*.[@b3]                                                              1997   61/M         AD
  13     Leo *et al*.[‡](#tf1-3){ref-type="table-fn"}                                       1999   59/M         LCC
  14     Saito *et al*.[‡](#tf1-3){ref-type="table-fn"}                                     1999   59/M         AD
  15     Cafferata *et al*.[‡](#tf1-3){ref-type="table-fn"}                                 2004   68/M         AD
  16     Kato *et al*.[‡](#tf1-3){ref-type="table-fn"}                                      2005   60/M         AD
  17     Pujol *et al*.[@b5]                                                                2007   75/F         SQ
  18     Moriyama *et al*.[‡](#tf1-3){ref-type="table-fn"}                                  2008   45/M         LCC
  19     Gladwish *et al*.[@b6]                                                             2010   81/F         SQ
  20     Haruki *et al*.[@b4]                                                               2010   69/F         AD
  21     Mizuno *et al*.[@b7]                                                               2011   62/M         LCC
  22     Furukawa *et al*.[@b8]                                                             2011   56/M         SQ
  23     Choi *et al*.[@b9]                                                                 2013   71/M         SQ
  24     Hwang *et al*.[@b10]                                                               2013   62/M         NSCLC
  25     Present case                                                                       2014   86/F         LCNEC

Literature reviews previously published by

Kappauf *et al*.[@b3] and

Haruki *et al*.[@b4] are included. AD, adenocarcinoma; F, female; LCC, large cell carcinoma; LCNEC, large cell neuroendocrine carcinoma; M, male; NSCLC, non-small cell lung cancer; SQ, squamous cell carcinoma.

In our case, the tumor spontaneously regressed and subsequently showed rapid progression after the initiation of glucocorticoid treatment. Although several possible mechanisms of spontaneous regression have been presented, the details remain unclear.[@b1],[@b3] Among the proposed mechanisms, immunological activation may be one of the more reasonable. Infiltration with CD8-positive lymphocytes[@b4] and a high degree of natural killing activity[@b11] have been reported within malignant tissues. If immunological activation was involved with the spontaneous regression of the tumor in our case, it may be reasonable to surmise that immunosuppression from glucocorticoid treatment could have affected the rapid progression of the tumor. However, it was difficult to fully evaluate the reasons for spontaneous regression in this case because blood and tissue samples were not available from the time of spontaneous regression.

Conclusion
==========

This is the first report of spontaneous regression followed by progression in lung LCNEC. Physicians and surgeons should be aware that the radiographic regression of a pulmonary nodule does not necessarily exclude the possibility of lung cancer.
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